FDA Inspection
Axogen CorporationAxogen Corporation – FDA Inspection, Nov 20, 2018
Record Details
This FDA Inspection record concerns Axogen Corporation, with an inspection on November 20, 2018, issued by the Center for Biologics Evaluation and Research, covering biologics.
View Company Profile
ID · 6c574dbc-677c-4b2f-ae65-d7b0959d53d0
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1072238
- FDA center
- Biologics
- Project area
- Human Cellular, Tissue, and Gene Therapies
- Outcome
- Form 483 issued
FDA Citations
1- 21 CFR 1271.290(b)Establishing a system
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Axogen Corporation
4| Date | Classification | Office | Project area |
|---|---|---|---|
| January 8, 2026 | Not classified | Dallas District Office | |
| June 19, 2025 | Not classified | Dallas District Office | |
| July 28, 2022 | NAI | Center for Devices and Radiological Health | Postmarket Assurance: Devices |
| October 13, 2015 | NAI | Center for Biologics Evaluation and Research | Human Cellular, Tissue, and Gene Therapies |
Other documents for Axogen Corporation
- FDA Inspection 1298590 - 2026-01-08
- FDA Inspection 1275112 - 2025-06-19
- FDA Inspection 1177562 - 2022-07-28
- FDA Inspection 946545 - 2015-10-13
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.